On this week’s WTR Small-Cap Spotlight, we speak with Apimeds CEO Erik Emerson about the newly NYSE listed company and the development of Apitox, a purified honeybee venom, for knee osteoarthritis and multiple sclerosis. We discuss the therapeutic properties of bee venom and the clinical/regulatory plans to bring Apitox to the US market. Listen to learn more about Apimeds and its novel approach to treat inflammatory pain.
You can listen to this episode and more on the WTR Biotech Spotlight at the links below!
Apple: https://podcasts.apple.com/us/podcast/wtr-biotech-spotlight/id1795488592
Spotify: https://open.spotify.com/episode/7KUMWuGavyAuDEs2527rp2?si=22adef2e0f304634